PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC).

被引：13

作者：

Hussain, Maha

Fizazi, Karim

Saad, Fred

Rathenborg, Per

Shore, Neal D.

Demirhan, Eren

Modelska, Katharina

De Phung

Krivoshik, Andrew

Sternberg, Cora N.

机构：

[1] Northwestern Univ, Chicago, IL USA

[2] Univ Paris Sud, Inst Gustave Roussy, Canc Med, Villejuif, France

[3] Ctr Hosp Univ Montreal, CRCHUM, Montreal, PQ, Canada

[4] Herlev Hosp, Herlev, Denmark

[5] Carolina Urol Res Ctr, Myrtle Beach, SC USA

[6] Pfizer Inc, San Francisco, CA USA

[7] Astellas Pharma Inc, Leiden, Netherlands

[8] Astellas Pharma Inc, Northbrook, IL USA

[9] San Camillo Forlanini Hosp, Rome, Italy

来源：

关键词：

D O I：

10.1200/JCO.2018.36.6_suppl.3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：2